CClinicalTrials.gg
Status unknownNCT04628923Updated Nov 16, 2020

Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach for Hip Surgery

A Phase 3 interventional study of QUADRATUS LUMBORUM BLOCK in Self Efficacy, sponsored by Beni-Suef University. Status unknown. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by Beni-Suef University · Phase 3, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
30 Years to 60 Years
Sex
All
01

Study summary

The quadratus lumborum block (QLB) was first described by Blanco. it is a compartment block procedure during which a local anesthetic is injected into the muscle plane of the quadratus lumborum (QL) muscle under ultrasound guidance Currently, QLB is divided into four types based on the injection point of the local anesthetic: lateral, anterior, posterior, and intramuscular QLB. QLB is widely used for various types of abdominal surgeries (

Read the detailed description

the investigators will evaluate the anesthetic efficacy of quadratus lumborum block by paraspinous sagittal shift approach for hip surgery by injecting 30 ml of 0. 5% bupivacaine.

02

Conditions studied

  • Self Efficacy
03

In context

Lead sponsor

Beni-Suef University is the lead sponsor of 333 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

-ASA I and II

Exclusion criteria

Exclusion Criteria:

  • Contraindications for regional blocks (eg. Patient refusal Infection at the injection site, coagulopathy)
  • Allergic reaction to drugs.
  • opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    QLB

    With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly. The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively.

    Other: QUADRATUS LUMBORUM BLOCK

Interventions

  • OtherQUADRATUS LUMBORUM BLOCK

    QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH

06

What researchers measure

Primary outcomes

  1. sensory and motor block level

    BY PIN PRICK

    Time frame: immediately after the intervention/procedure/surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04628923
Lead sponsor
Beni-Suef University
Responsible party
doaa rashwan (Assistant professor Doaa Rashwan, Beni-Suef University) — Principal investigator
First posted
Nov 16, 2020
Start date
Nov 20, 2020 (estimated)
Primary completion
Dec 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Nov 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion